Akebia Therapeutics Inc (AKBA) - Friday, Oct 25, 2024
Despite their challenges, the company's stock is seen as undervalued and has the potential to reach a price target of $5.00+.
577 Views
Otsuka Holdings (4578 JP) 1Q22: Global Products Continued Double-Digit Revenue Growth
Otsuka reported 13% y/y revenue growth in Q1, driven by four global products and reiterated 2022 guidance. Despite recent pipeline blues, Otsuka’s...
480 Views
Radicava Sales Uptake Key to Maintaining Flat Top-Line Over the Next 3-5 Years
We reiterate our “Equal-weight” rating on the stock after reviewing our model post FY17 (YE Mar-18) earningsDomestic pharma, contributing >70%...
984 Views
No more insights